Abstract： Objective： To observe the clinical effect of Qingre Jiedu prescription combined with interferon on cervical human papillomavirus(HPV) infection. Methods：Seventy-five patients with cervical HPV infection were selected and divided into the interferon group(37 cases) and the combination group(38 cases) according to random number table method. The interferon group was treated with recombinant human interferon α2b vaginal effervescent tablets，and the combination group was additionally treated with Qingre Jiedu prescription based on the treatment of the interferon group. Both groups were treated for three menstrual cycles. The clinical effect， HPV negative conversion rate， levels of inflammatory cytokine and adverse reactions were compared between the two groups. Results：The clinical effect in the combination group was better than that in the interferon group(Z=2.698，P＜0.05). After treatment，the negative HPV conversion rate in the combination group was 81.58%，higher than that of 67.57% in the interferon group(χ2=5.176，P＜0.05). After treatment，the levels of interleukin- 2(IL- 2) and the value of interleukin- 2/interleukin- 4(IL- 4) in vaginal rinse fluid in the combination group were higher than those in the interferon group(P＜0.05)；the IL-4 level was lower than in the combination group(P＜0.05). During treatment， no obvious adverse reactions occurred in both groups. Conclusion： Qingre Jiedu prescription combined with interferon for cervical HPV infection，can effectively promote HPV negative rate，regulate the local vaginal immune balance， and the safety is great.